AWM
VRTX icon

Altium Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Altium Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,169
Closed -$276K – 390
2020
Q4 		$276K Buy
1,169
+97
+9% +$22.3K 0.02% 298
2020
Q3 		$292K Buy
1,072
+24
+2% +$6.62K 0.03% 270
2020
Q2 		$304K Buy
1,048
+68
+7% +$18.4K 0.03% 268
2020
Q1 		$233K Buy
+980
New +$225K 0.03% 270

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Altium Wealth Management's VRTX Position: Q1 2021 in Review

Altium Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 1,169 shares — an estimated $276K sold.

Altium Wealth Management first reported a position in VRTX in Q1 2020 and held it in 4 quarters. The position peaked at $304K in Q2 2020. 1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • Altium Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Altium Wealth Management sold 1,169 Vertex Pharmaceuticals shares in Q1 2021, an estimated $276K.
  • Altium Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Altium Wealth Management's Vertex Pharmaceuticals position peaked at $304K in Q2 2020.
  • 1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Altium Wealth Management's 13F filing for Q1 2021, filed 6 May 2021.